About half of all malignant brain tumours are glioblastomas, the deadliest form of brain cancer with a median survival rate of 14 months.

"Surgery for glioblastoma is very challenging, and patients almost always experience a relapse," said the study's senior author, Min Li, Ph.D., a professor of medicine, surgery and cell biology at the University of Oklahoma College of Medicine. "By better understanding why these brain tumours are so aggressive, we hope to open up paths for new treatments."

Under normal conditions, ZIP4 plays a positive role, transporting and maintaining the right amount of zinc for good health. However, when brain cancer is present, ZIP4 takes on a different role. In the case of glioblastoma, it triggers a series of events:

"Everything starts with the fact that ZIP4 is overexpressed in glioblastoma," Li said. "That triggers all these downstream events that help the tumour to grow."

Li's research team also tested a small-molecule inhibitor to target ZIP4 and TREM1. The inhibitor attached to both proteins, stopping their actions and slowing tumour growth. "This tells us that ZIP4 and TREM1 may be promising therapeutic targets," he said.

Neurosurgeon, OU College of Medicine Executive Dean and study co-author Ian Dunn, M.D., said the findings are an encouraging step toward combating the aggressive cancer.

"These results are really exciting in such a debilitating cancer. The hope and promise is to translate these findings to novel treatment approaches to improve the lives of our patients," said Dunn, who has been treating patients with brain tumours for over 20 years.

This is one of Li's first major publications on glioblastoma, but ZIP4 has been a focus of his pancreatic cancer research for many years. He discovered that overexpression of ZIP4 causes pancreatic cancer cells to be more resistant to chemotherapy and prompts tumour cells to transform themselves so they can stealthily travel to the body's other organs. In addition, he found that ZIP4 plays a role in the onset of cachexia, a muscle-wasting condition that affects the majority of patients with pancreatic cancer.